More than 2,500 test microinjections completed with expanded lab staff to boost throughput
ANN ARBOR, Mich., – June 12, 2018 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers announces today that the Company has completed more than 2,500 microinjections using the recently announced new spider silk DNA synthesis methodology. This new method allows for faster creation of larger and more complex spider silk proteins. Larger and more complex proteins are believed to produce improved silk strength, toughness, and elasticity. These improved recombinant spider silk fibers will allow the Company to target an expanded set of end market applications.
To support this expanded research and development capability, the Company added two laboratory staff for increased testing throughput. The additional lab staff members have been trained and have conducted the majority of the microinjection effort.
By implementing this new validated protocol and completing these initial microinjections, the Company is looking forward to creating new transgenics, at Kraig Labs’ U.S. R&D headquarters, with an abridged development cycle and enhanced materials performance. The transgenics created using the new protocols are expected to be transitioned into Prodigy Textiles’, the Company’s recently announced Vietnamese subsidiary, commercial production process.
“Thanks to our lab and production teams’ considerable collaborative effort, this new methodology has already demonstrated the potential to significantly reduce our development timelines. To see it put into practice so quickly and to have already completed the first 2,500 test microinjections is very impressive,” said Jon Rice, COO. “I look forward to seeing this capability enable the next generation of recombinant spider silk fibers.”
To view the most recent edition of Kraig’s Spider Sense quarterly newsletter and/or to sign up for Company alerts, please go to www.KraigLabs.com/newsletter
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.
The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Ben Hansel, Hansel Capital, LLC